Friday Morning Live Cases: Coronary and Structural Interventions

Dr. Kendra Grubb is the surgical director of the Emory Structural Heart and Valve Center. Prior... Dr. Kendra Grubb is the surgical director of the Emory Structural Heart and Valve Center. Prior to joining Emory in 2018, she was the director of minimally invasive cardiac surgery and the surgical director of the heart valve program at the University of Louisville. Dr. Grubb is a champion for combating women's heart disease and is dedicated to improving the lives of all patients, both male and female, through innovation and by building collaborative teams to promote a patient-centered approach to the treatment of cardiovascular disease. Dr. Grubb has led and participated in multiple clinical trials of innovative cardiac surgery technologies, including studies of transcatheter aortic valve replacement (TAVR), MitraClip percutaneous therapy, and the GORE conformable TAG thoracic endoprosthesis for the primary treatment of aneurysms of the descending thoracic aorta. Dr. Grubb received her MD degree from the Keck School of Medicine and her Master of Health Administration from the Sol Price School of Public Policy. She completed her general surgery residency at the University of Illinois at Chicago, her fellowship in cardiothoracic surgery at the University of Virginia in Charlottesville, and her fellowship in interventional cardiology and transcatheter therapies at New York Presbyterian/Columbia University Medical Center. Read more Show less

Michael Slack works at University of Maryland Medical Center, Baltimore, MD, USA.

Gregg W. Stone, MD, FACC, MSCAI is an interventional cardiologist and Director of Academic... Gregg W. Stone, MD, FACC, MSCAI is an interventional cardiologist and Director of Academic Affairs for the Mount Sinai Heart Health System and Professor of Medicine (Cardiology) and Professor of Population Health Sciences and Policy at the Icahn School of Medicine at Mount Sinai in New York, NY. Dr. Stone has served as the national or international principal investigator for more than 120 national and international multicenter randomized trials (many of which have led to new device approval or indications in the US), has authored more than 2000 manuscripts and abstracts published in the peer-reviewed literature, and has delivered thousands of invited lectures around the world. With a 2018 H-factor of 152, Dr. Stone was recently listed in Nature Medicine as one of the most prolific authors in science. Dr. Stone's areas of expertise include interventional therapies of acute coronary syndromes, myocardial infarction and cardiogenic shock; drug-eluting stents and bioresorbable scaffolds; left main and complex coronary artery disease intervention; antiplatelet and antithrombotic pharmacotherapies; transcatheter valve repair and replacement; interventional hypertension and heart failure therapies; left atrial appendage closure; intravascular imaging (IVUS, OCT and NIRS); vulnerable plaque diagnosis and treatment; adjunctive interventional devices including atherectomy, distal embolic protection, thrombectomy, covered stents, chronic total occlusion devices, and brachytherapy; saphenous vein graft therapies; contrast nephropathy; clinical trial design; and regulatory issues. Dr. Stone is the director of TCT, the world's largest symposium devoted to interventional cardiology and vascular medicine. Dr. Stone founded the annual National Interventional Cardiology Fellow's Course and Transcatheter Valve Therapies TVT), the Chronic Total Occlusion (CTO) Summit, and co-directs multiple other meetings in the US, China, Russia, Europe, S. Korea and elsewhere. Read more Show less